Afficher la notice abrégée

Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity

dc.rights.licenseopenen_US
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorMATIAS, Isabelle
hal.structure.identifierUniversity of Copenhagen = Københavns Universitet [UCPH]
dc.contributor.authorLEHMANN, E.W.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorZIZZARI, Philippe
hal.structure.identifierUniversity of Copenhagen = Københavns Universitet [UCPH]
dc.contributor.authorBYBERG, Sarah
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorCOTA, Daniela
hal.structure.identifierUniversity of Copenhagen = Københavns Universitet [UCPH]
dc.contributor.authorTOREKOV, Signe Sørensen
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorQUARTA, Carmelo
dc.date.accessioned2024-01-30T13:13:05Z
dc.date.available2024-01-30T13:13:05Z
dc.date.issued2023-11-04
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/187635
dc.description.abstractEnObjective: N-acylethanolamines (NAEs) include endocannabinoid (EC) and EC-related molecules that impact the anti-obesity and anti-diabetic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RA) in animal studies. However, the clinical relevance of these findings remains to be determined. Here, we tested whether GLP-1RA treatment affects circulating NAE levels and whether NAEs may predict the efficacy of GLP-1RA treatment in humans with obesity undergoing weight loss maintenance. Materials and methods: We profiled plasma levels of NAEs in participants with obesity undergoing weight loss maintenance with (n = 23)/or without (n = 20) treatment with the GLP-1RA liraglutide. NAE levels were measured at three different time points: before the start of the study, at the end of the diet-induced weight loss, and after 52-weeks treatment. Linear regression analyses were used to investigate whether pharmacological responses could be predicted by NAEs levels. Results: Liraglutide treatment reduced plasma concentrations of the NAE and oleoyl-ethanolamide (OEA), without altering arachidonoyl-ethanolamide (AEA) levels and palmitoyl-ethanolamide (PEA) levels. High pre-treatment levels of OEA were predictive of superior compound-mediated effects on fasting insulin and triglyceride levels. High pre-treatment PEA and AEA levels were also predictive of superior Liraglutide-mediated effects on triglyceride levels. Conclusions: Our data suggests that specific NAEs such as OEA and AEA are promising biomarkers of GLP-1RA metabolic efficacy in humans with obesity during weight loss maintenance. Plasma profiling of EC-related molecules may be a promising strategy to tailor GLP-1R-based therapies to individual needs in obesity and diabetes management. © 2023, The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
dc.language.isoENen_US
dc.subject.enEndocannabinoid-related molecules
dc.subject.enEndocannabinoids
dc.subject.enGLP-1R agonist
dc.subject.enObesity
dc.title.enEndocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity
dc.title.alternativeJ Endocrinol Investen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s40618-023-02228-8en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
bordeaux.journalJournal of Endocrinological Investigationen_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPhysiopathologie de l'équilibre énergétique et obésitéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04426376
hal.version1
hal.date.transferred2024-01-30T13:13:07Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Endocrinological%20Investigation&rft.date=2023-11-04&rft.au=MATIAS,%20Isabelle&LEHMANN,%20E.W.&ZIZZARI,%20Philippe&BYBERG,%20Sarah&COTA,%20Daniela&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée